Prognose

Das durchschnittliche Kursziel der Analysten beträgt +7,70€(+492,31%). Der Median liegt bei +7,70€(+492,31%).

Kaufen	2
Halten	1
Verkaufen	0

Scoring-Modelle

Dividenden-Strategie	0 / 15
HGI-Strategie	5 / 18
Levermann-Strategie	-2 / 13

News

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the granting of inducement awards to a new employee as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by the Compensation Committee of the Company's Board of Directors and were made as material inducements to the recipients' employment with the Company. In all cases, vesting is subject to the recipient's continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company's 2020 Inducement Incentive Plan.» Mehr auf globenewswire.com
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the granting of inducement awards to new employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by the Compensation Committee of the Company's Board of Directors and were made as material inducements to the recipients' employment with the Company. In all cases, vesting is subject to the recipient's continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company's 2020 Inducement Incentive Plan.» Mehr auf globenewswire.com
Neuronetics and Greenbrook TMS Announce Closing of Transaction
MALVERN, Pa. and TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (“Neuronetics”) and Greenbrook TMS Inc. (OTCMKTS: GBNHF) (“Greenbrook”, and together with Neuronetics, the “Combined Company”) today announced that they have successfully completed the previously announced transaction whereby Neuronetics acquired all of the issued and outstanding common shares of Greenbrook (the “Greenbrook Shares”) by way of a court-approved plan of arrangement under the Business Corporations Act (Ontario) (the “Arrangement”). Each Greenbrook Share outstanding immediately prior to the effective time of the Arrangement was exchanged for 0.01021 of a share of common stock of Neuronetics (the “Exchange Ratio”) upon closing of the Arrangement.» Mehr auf globenewswire.com

Unternehmenszahlen

Im letzten Quartal hatte NEURONETICS INC. DL-,01 einen Umsatz von 16,64 Mio€ und ein Nettoeinkommen von −11,98 Mio€

(EUR)	Sep. 2024	YOY
Umsatz	+16,64 Mio	1,50%
Bruttoeinkommen	+12,57 Mio	13,14%
Nettoeinkommen	−11,98 Mio	35,05%
EBITDA	−9,97 Mio	36,94%

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+41,05 Mio€
Anzahl Aktien	32,07 Mio
52 Wochen-Hoch/Tief	+4,88€ - +0,50€
Dividenden	Nein
Beta	2,22
KGV (PE Ratio)	−1,11
KGWV (PEG Ratio)	+0,11
KBV (PB Ratio)	+4,29
KUV (PS Ratio)	+0,59

Unternehmensprofil

Neuronetics, Inc. ist ein Medizintechnikunternehmen im kommerziellen Stadium, das Produkte für Patienten mit neurologischen Störungen in den Vereinigten Staaten und international entwickelt und vermarktet. Das Unternehmen bietet das NeuroStar Advanced Therapy System an, eine nicht-invasive und nicht-systemische Behandlung in der Praxis zur Behandlung erwachsener Patienten mit schweren depressiven Störungen. Das NeuroStar Advanced Therapy System nutzt die transkranielle Magnetstimulation, um ein gepulstes Magnetfeld von MRT-Stärke zu erzeugen, das elektrische Ströme induziert, die bestimmte Hirnregionen stimulieren, die mit der Stimmung in Verbindung stehen. Das Unternehmen vertreibt seine Produkte über sein Vertriebs- und Kundendienstteam an Psychiater. Neuronetics, Inc. wurde im Jahr 2001 gegründet und hat seinen Hauptsitz in Malvern, Pennsylvania.